Jackie Schumacher

[Rallybio @rallybio]

Rallybio has dosed the first participant in the RLYB212 Ph2 clinical trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT. Key data readouts from the sentinel participant are expected in 2Q 2025 and 3Q 2025.

#RareDisease #RLYB212 #Rallybio $RLYB

[Rallybio @rallybio]

It was great to see our colleagues Mark Ma and Amanda Hayward, along with many of our partners including Huiying Zhi from Versiti, at the ASH conference earlier this week to share exciting data from our RLYB212 and RLYB332 programs!

[Rallybio @rallybio]

Were you able to make it to @ASH_hematology this year?

If so, you may have seen some exciting new data from the Rallybio pipeline shared throughout the weekend on RLYB212 and RLYB332!

Check out both posters on our site here: https://t.co/Wnx9AuEQ1u

[Rallybio @rallybio]

Our CFO Jon Lieber proudly represented Rallybio at last night's #Fierce50 Gala, where we were an Innovation honoree! 🥂

We have much to look forward to next year and are another step closer to transforming lives. Thank you, @FiercePharma! #RareDisease

https://t.co/WVvqrSK7mg

[Rallybio @rallybio]

🌴In Coral Gables today for the 7th Annual Evercore HealthCONx Conference?

Don’t miss our co-founder and CEO Dr. Stephen Uden’s fireside chat Wednesday, December 4th at 12:30 p.m. ET.

Listen live to today’s webcast: https://t.co/dv3w6j7d98

[Rallybio @rallybio]

We discussed recent updates and our plans to advance RLYB116, an innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases.

https://t.co/E8xQV9wQzD

#RLYB116 #RareDisease

[Rallybio @rallybio]

As we gather this Thanksgiving, we’re grateful for the innovation, resilience, and passion of those who drive forward our work every day.
Thank you to our team, partners, and community for making our work possible. Wishing you and your loved ones a safe and joyful holiday season

[Rallybio @rallybio]

🌴If you’re Coral Gables for Evercore’s HealthCONx Conference next week, don’t miss our co-founder and CEO Dr. Stephen Uden’s fireside chat on Wednesday, December 4th at 12:30 p.m. ET.
https://t.co/YXtUEDFJAj

[Rallybio @rallybio]

We’re proud to announce the publication of our manuscript, “Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody,” in Clinical Pharmacology and Therapeutics: Pharmacometric & Systems Pharmacology.

[Rallybio @rallybio]

🚨 Today, Rallybio announced the initiation of the Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT).

[Jackie Schumacher @JackieSchu53]

Great for pregnant women and an outstanding achievement for @rallybio !

[Rallybio @rallybio]

FNAIT is officially on notice 📢 today, as we're announcing the approval of our lead program, RLYB212, to move into Phase 2 trials in pregnant women at higher risk of alloimmunization and FNAIT (fetal and neonatal alloimmune thrombocytopenia): https://t.co/VmKoEubBps

[Jackie Schumacher @JackieSchu53]

Rallybio received EU approval for Phase 2 clinical trial! What a great milestone for pregnant women and the company.

[Rallybio @rallybio]

We are proud to announce that Rallybio is a 2024 Fierce 50 report honoree. 👏 https://t.co/WVvqrSKFbO

[Rallybio @rallybio]

Read more about the impact and what we can do to improve women's health here: https://t.co/sO7Qv7EgMH

#WomensHealth #ResearchMatters

[Rallybio @rallybio]

🗣️#YaleInnovation2024 Attendees: On-site in New Haven for the 10th annual Summit? Head to the Biotech showcases in the OC Marsh Auditorium on May 29th from 1:30-3:40 pm ET to learn more about the future of rare diseases from our very own co-founder and CEO, Stephen Uden! #biotech

[Rallybio @rallybio]

Did you know that this week is #FNAITAwarenessWeek? FNAIT, or fetal and neonatal alloimmune thrombocytopenia, is a rare but severe condition that can affect pregnant women and their babies.

[Rallybio @rallybio]

Our CEO, Steve Uden, will participate in today’s “Orphan, Bone and Neuromuscular Diseases” panel at 9:10 a.m. ET at the Cowen 44th Annual Health Care Conference.

Listen live to today’s webcast: https://t.co/qRJ6ECRmeX #CowenHealthcare #Cowen2024

[Rallybio @rallybio]

There are 300 million people worldwide living w/ a #raredisease. DYK: #FNAIT is a rare disease that occurs when there is a mismatch between the mother’s platelets & those of the baby, resulting in the destruction of platelets in the fetus or infant.
#RareDiseaseDay

[Rallybio @rallybio]

On Wednesday, January 10 at 8:15 a.m. PT (11:15 a.m. ET), #TeamRallybio will be presenting @jpmorgan #JPM24 Healthcare Conference. Excited for the opportunity, hope to see you there!
Read more: https://t.co/LHPDFtbP4g #JPM2024 #biotech #scientificinnovation #drugdevelopment

[Rallybio @rallybio]

Grateful for the strides made in supporting those affected by #rarediseases. As we step into a new year, our commitment to innovation, resilience, and hope remains strong. Wishing you a #HappyNewYear